Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
2 other identifiers
observational
270
1 country
2
Brief Summary
To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \[LNG-IUS\]).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2026
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 22, 2026
CompletedFirst Posted
Study publicly available on registry
February 3, 2026
CompletedStudy Start
First participant enrolled
February 12, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2030
February 25, 2026
February 1, 2026
2 years
January 22, 2026
February 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Patient Utility Questionnaire
Through study completion; an average of 1 year
Study Arms (2)
Phase 1
Identify decisional needs, patient values and experiences
Phase 2
Develop and pilot test a web-based shared medical decision tool
Interventions
Patient Preference Utility Assessment and Questionnaires
Eligibility Criteria
MD Anderson Cancer Center
You may qualify if:
- Unaffected women
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must be premenopausal
- Must not have a prior history of EC or complex atypical hyperplasia
- Must provide written, informed consent
- No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member
- Affected women
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must have a prior history of EC or complex atypical hyperplasia
- Must provide written, informed consent
- No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member
- Healthcare Providers
- Physicians or advanced practice providers (physician assistants, nurse practitioners) from Family Medicine, Obstetrics \& Gynecology, Internal Medicine, or Endocrinology
- +3 more criteria
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
The Harris Health System (LBJ)
Houston, Texas, 77026, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Larissa A Meyer, MD
M.D. Anderson Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 22, 2026
First Posted
February 3, 2026
Study Start
February 12, 2026
Primary Completion (Estimated)
February 1, 2028
Study Completion (Estimated)
February 1, 2030
Last Updated
February 25, 2026
Record last verified: 2026-02